In order to evaluate the potential role of BRD9 in therapeutic response, we assessed publicly available data from the TCGA database, and found that BRD9 is amplified in about 15% of ovarian cancers (Fig. 5a). This evidence concerns the gene BRD9 and ovarian cancer.